Pacira BioSciences, Inc. Stock Analysis & AI Score
Pacira BioSciences, Inc. (PCRX) has an ST Score of 58.6 (B-), driven by its Profitability (A+) and held back by its Growth (D). Analysts rate it Hold with a $29.40 price target (+15.0% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Pacira BioSciences, Inc. (PCRX) has an ST Score of 58.6 (B-), driven by its Profitability (A+) and held back by its Growth (D). Analysts rate it Hold with a $29.40 price target (+15.0% upside).
- Strongest
- ProfitabilityA+
- Weakest
- GrowthD
All factor grades
- ProfitabilityA+
- MomentumA
- ForecastB-
- Financial StrengthC+
- ValuationD+
- GrowthD
- Piotroski8/9
Contact
PCRX stock: frequently asked questions
What is PCRX's ST Score?
Pacira BioSciences, Inc. (PCRX) has an ST Score of 58.6 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is PCRX a buy, hold, or sell?
Analysts rate PCRX a Hold, with a price target of $29.40 (+15.0% vs the current price). Our ST Score grades it B- (58.6/100). The ST Score is a data-driven signal, not a recommendation.
What are PCRX's factor grades?
Valuation D+, Profitability A+, Financial Strength C+, Momentum A, Growth D, Forecast B-.
What is PCRX's valuation grade?
Pacira BioSciences, Inc. (PCRX) earns a valuation grade of D+, measured against Drug Manufacturers - Specialty & Generic peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is PCRX's growth grade?
Pacira BioSciences, Inc. (PCRX) earns a growth grade of D, measured against Drug Manufacturers - Specialty & Generic peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is PCRX's profitability grade?
Pacira BioSciences, Inc. (PCRX) earns a profitability grade of A+, measured against Drug Manufacturers - Specialty & Generic peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is PCRX's financial strength grade?
Pacira BioSciences, Inc. (PCRX) earns a financial strength grade of C+, measured against Drug Manufacturers - Specialty & Generic peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for PCRX?
The average analyst price target for Pacira BioSciences, Inc. (PCRX) is $29.40 from 36 analysts, which is +15.0% versus the recent price of $25.56.
What is PCRX's Piotroski score?
Pacira BioSciences, Inc. (PCRX) has a Piotroski F-Score of 8 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.